supported by the National Key Research and Development Program of China(Nos.2022YFC2502600 and 2022YFC2502606);the National Natural Science Foundation of China(Nos.82170206 and 82170208);CAMS Innovation Fund for Medical Sciences(Nos.2019-I2M-5-034 and 2022-I2M-C&T-B-121);Peking University People’s Hospital Research and Development Funds(No.RZ2022-02);Tongzhou District Distinguished Young Scholars(No.JCQN2023009);Shanghai Municipal Health Commission Project of Disciplines of Excellence(No.20234Z0002)。
The cooccurrence of NPM1,FLT3-ITD,and DNMT3A mutations(i.e.,triple mutation)is related to dismal prognosis in patients with acute myeloid leukemia(AML)receiving chemotherapy alone.In this multicenter retrospective coh...
supported by the National Natural Science Foundation of China(No.32222046,China);the Sichuan Science and Technology Program(Nos.2022NSFSC0823,2023NSFSC193,2022NSFSC0793,China);the 1·3·5 Project for Disciplines of Excellence,West China Hospital,Sichuan University(No.ZYJC21022,China).
FMS-like tyrosine kinase 3(FLT3)is a viable and important therapeutic target for acute myeloid leukemia(AML).FLT3 internal tandem duplication(FLT3-ITD)mutations have been identified in approximately 30%of AML patients...
This work was supported by the National Natural Science Foundation of China(82170213 to L.X.,81970161 to Q.L.);the National Key Research and Development Projects of China(2021YFC2500301-4 to Q.L.,2022YFC2502600-5 to L.X.);Clinical Research Program of Nanfang Hospital,Southern Medical University(2021CR002 to L.X.).
Sorafenib therapy improves overall survival(OS)in patients with FLT3 internal tandem duplication(ITD)acute myeloid leukemia(AML)undergoing allogeneic hematopoietic stem cell transplantation.We explored the efficacy of...